ERNA
Ernexa Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Ernexa Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
No thesis.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Annual filing, covered
10-K parsed · Mar 13 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 13 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
—
—
No trades yet today.
No trades yet today.
Ernexa Therapeutics Inc.
1.95
−0.07 · −3.47%
post 1.94 −0.51%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Ernexa Therapeutics Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Ernexa Therapeutics Inc..
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| Vanguard Fiduciary Trustindex-like | $55,434 | 41.57% | −67.24% |
| Dauntless Investment | $39,900 | 29.92% | −99.02% |
| Vanguardindex-like | $37,799 | 28.34% | −78.55% |
| BlackRockindex-like | $219 | 0.16% | −95.98% |
| BNP Paribas Arbitrage | $7 | 0.01% | −90.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguard Fiduciary Trustindex-like | $55,434 | 41.57% | −67.24% |
| Dauntless Investment | $39,900 | 29.92% | −99.02% |
| Vanguardindex-like | $37,799 | 28.34% | −78.55% |
| BlackRockindex-like | $219 | 0.16% | −95.98% |
| BNP Paribas Arbitrage | $7 | 0.01% | −90.00% |
−96.99%
shares held · 5 largest managers
—
—
Expected move
No implied move.